Cardiovascular Safety of Janus Kinase Inhibitor Therapy in a Multi-ethnic Population

Musculoskeletal Care 2023 doi 10.1002/msc.1853 Epub ahead of print

This study by Sunmboye, et al. investigated the relationship between CV event incidence and age in a multi-ethnic population that received JAK inhibitor therapy. They concluded that JAK inhibitor therapy was generally safe in a multi-ethnic population with a large age range, but they did find a statistically significant but numerically small positive correlation between age and CV incidence.

In this retrospective cross-sectional study, CV event incidence was identified in 309 patients with an autoimmune rheumatic disease. Within this patient cohort, 73.5% were Caucasian and 25.6% were South Asian. They observed 14 CV events in the total population.